Data gathered: April 15
AI Stock Analysis - Mirum Pharmaceuticals (MIRM)
Analysis generated March 20, 2025. Powered by Chat GPT.
Mirum Pharmaceuticals is a biopharmaceutical company focused on developing novel therapies for rare liver diseases. With a pipeline that includes treatments for cholestatic liver diseases, Mirum aims to address unmet medicinal needs in the child and adult population. The company's flagship product, Maralixibat, has shown promising clinical results, contributing significantly to its revenue generation and business outlook.
Stock Alerts - Mirum Pharmaceuticals (MIRM)
 |
Mirum Pharmaceuticals | April 10 Price is down by -6.6% in the last 24h. |
|
Mirum Pharmaceuticals | April 9 Price is down by -5.1% in the last 24h. |
|
Mirum Pharmaceuticals | April 8 Price is down by -6.2% in the last 24h. |
|
Mirum Pharmaceuticals | April 1 Employee Rating is up by 2.6% over the last month. |
Alternative Data for Mirum Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 11 | Sign up | Sign up | Sign up |
| Sentiment | 89 | Sign up | Sign up | Sign up |
| Webpage traffic | 5,000 | Sign up | Sign up | Sign up |
| Employee Rating | 78 | Sign up | Sign up | Sign up |
| Google Trends | 12 | Sign up | Sign up | Sign up |
| Patents | 7 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 29 | Sign up | Sign up | Sign up |
| Facebook Followers | 357 | Sign up | Sign up | Sign up |
| Instagram Followers | 421 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 14 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,576 | Sign up | Sign up | Sign up |
| Twitter Followers | 595 | Sign up | Sign up | Sign up |
| Twitter Mentions | 48 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 166 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 53 | Sign up | Sign up | Sign up |
| Linkedin Employees | 358 | Sign up | Sign up | Sign up |
About Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
| Price | $39.59 |
| Target Price | Sign up |
| Volume | 295,120 |
| Market Cap | $1.94B |
| Year Range | $37.85 - $53.16 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 10 - Finnhub |
|
 |
Mirum Pharmaceuticals (MIRM) Down 1.9% Since Last Earnings Report: Can It Rebound?March 28 - Yahoo |
 |
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives $58.20 Consensus Target Price from AnalystsMarch 27 - ETF Daily News |
Mirum Pharmaceuticals, Inc. - LIVMARLI Now Approved in Japan for ALGS and PFICMarch 27 - Finnhub |
|
 |
Mirum Pharmaceuticals partner Takeda receives approval for Livmarli in JapanMarch 27 - Thefly.com |
|
Swiss National Bank Acquires 1,300 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)March 27 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 89M | 56M | 33M | -14M | -6.8M | -0.298 |
| Q2 '24 | 78M | 55M | 23M | -25M | -19M | -0.520 |
| Q1 '24 | 71M | 51M | 20M | -25M | -21M | -0.540 |
| Q4 '23 | 67M | 52M | 15M | -36M | -27M | -0.660 |
| Q3 '23 | 48M | 39M | 8.6M | -24M | -23M | -0.570 |
Insider Transactions View All
| Howe Jolanda filed to sell 2,426 shares at $44.4. March 19 '25 |
| Heron Patrick J filed to buy 168,672 shares at $43.9. March 18 '25 |
| Radovich Peter filed to sell 18,672 shares at $44.2. March 18 '25 |
| Howe Jolanda filed to sell 4,841 shares at $44.4. March 18 '25 |
| Howe Jolanda filed to sell 6,647 shares at $44.7. March 18 '25 |
Similar companies
Read more about Mirum Pharmaceuticals (MIRM) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Mirum Pharmaceuticals?
The Market Cap of Mirum Pharmaceuticals is $1.94B.
What is the current stock price of Mirum Pharmaceuticals?
Currently, the price of one share of Mirum Pharmaceuticals stock is $39.59.
How can I analyze the MIRM stock price chart for investment decisions?
The MIRM stock price chart above provides a comprehensive visual representation of Mirum Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Mirum Pharmaceuticals shares. Our platform offers an up-to-date MIRM stock price chart, along with technical data analysis and alternative data insights.
Does MIRM offer dividends to its shareholders?
As of our latest update, Mirum Pharmaceuticals (MIRM) does not offer dividends to its shareholders. Investors interested in Mirum Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Mirum Pharmaceuticals?
Some of the similar stocks of Mirum Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.